Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Randall EC, Zadra G, Chetta P, Lopez BG, Syamala S, Basu SS, et al. Molecular Characterization of Prostate Cancer with Associated Gleason Score Using Mass Spectrometry Imaging. Mol Cancer Res. 2019;17(5):1155-1165.

Panarelli N, Tyryshkin K, Wong JJ, Majewski A, Yang X, Scognamiglio T, et al. Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing. Endocr Relat Cancer. 2019;26(1):47-57.

Gross MD, Awamlh BA, Shoag JE, Mauer E, Banerjee S, Margolis DJ, et al. Race and prostate imaging: implications for targeted biopsy and image-based prostate cancer interventions. BMJ Surg Interv Health Technol. 2019;1(1):e000010.

Frost EL, Mockus TE, Ren HM, Toprak M, Lauver MD, Netherby-Winslow CS, et al. PD-1 Dynamically Regulates Inflammation and Development of Brain-Resident Memory CD8 T Cells During Persistent Viral Encephalitis. Front Immunol. 2019;10:783.

Ahmed A, Crowson N, Magro CM. A comprehensive assessment of cutaneous Rosai-Dorfman disease. Ann Diagn Pathol. 2019;40:166-173.

Gomes AP, Ilter D, Low V, Rosenzweig A, Shen Z-, Schild T, et al. Dynamic Incorporation of Histone H3 Variants into Chromatin Is Essential for Acquisition of Aggressive Traits and Metastatic Colonization. Cancer Cell. 2019;36(4):402-417.e13.

Barry DM, McMillan EA, Kunar B, Lis R, Zhang T, Lu T, et al. Molecular determinants of nephron vascular specialization in the kidney. Nat Commun. 2019;10(1):5705.

Labbé DP, Zadra G, Yang M, Reyes JM, Lin CY, Cacciatore S, et al. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nat Commun. 2019;10(1):4358.

Sun Q, Welsh KJ, Bruns DE, Sacks DB, Zhao Z. Inadequate Reporting of Analytical Characteristics of Biomarkers Used in Clinical Research: A Threat to Interpretation and Replication of Study Findings. Clin Chem. 2019;65(12):1554-1562.

Khani F, Wobker SE, Hicks JL, Robinson BD, Barbieri CE, De Marzo AM, et al. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations. J Pathol. 2019;249(1):79-89.